A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y.
Coppo P, et al. Among authors: dossier a.
Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.
Blood. 2021.
PMID: 33150928
Free PMC article.